Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Novo Nordisk A/S (NVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novo Nordisk ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
102.43 -0.77    -0.75%
08/08 - Closed. Currency in USD ( Disclaimer )
After Hours
102.31
-0.12
-0.12%
19:51:47 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,321,443
  • Bid/Ask: 99.80 / 103.65
  • Day's Range: 102.00 - 103.71
Novo Nordisk ADR 102.43 -0.77 -0.75%

Novo Nordisk A/S reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was DKK 41,265 million compared to DKK 33,041 million a year ago. Net income was DKK 13,318 million compared to DKK 12,123 million a year ago. Basic earnings per share from continuing operations was DKK 5.87 compared to DKK 5.26 a year ago. Diluted earnings per share from continuing operations was DKK 5.86 compared to DKK 5.26 a year ago.For the six months, sales was DKK 83,296 million compared to DKK 66,845 million a year ago. Net income was DKK 27,528 million compared to DKK 24,746 million a year ago. Basic earnings per share from continuing operations was DKK 12.11 compared to DKK 10.73 a year ago. Diluted earnings per share from continuing operations was DKK 12.08 compared to DKK 10.71 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

NVO Income Statement

Gross margin TTM 83.92%
Operating margin TTM 42.68%
Net Profit margin TTM 32.14%
Return on Investment TTM 59.92%
 Total Revenue  Net Income
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Total Revenue 42031 38333 35622 33041
Gross Profit 35114 32092 29563 27494
Operating Income 19147 13634 15249 14779
Net Income 14210 10892 12119 12123

NVO Balance Sheet

Quick Ratio MRQ 0.66
Current Ratio MRQ 0.94
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 34.16%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Total Assets 197136 194508 174084 158095
Total Liabilities 130586 123762 107972 92536
Total Equity 66550 70746 66112 65559

NVO Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  24.67%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Period Length: 3 Months 0 Months 9 Months 6 Months
Cash From Operating Activities 23586 55000 58017 36510
Cash From Investing Activities -1907 -31605 -11002 -6367
Cash From Financing Activities -19135 -25493 -30042 -18311
Net Change in Cash 2489 -1507 17264 12001
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVO Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
ramu g
ramu g Aug 03, 2022 11:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
novo very expensive drug market hemophilia drug big profitible business
Asterix Hr
Asterix Hr Dec 15, 2021 7:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Novo Nordisk announced plans to invest more than 17 billion Danish kroner ($2.58 billion) in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
daemin jeong
daemin jeong Nov 02, 2021 5:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sure, best company
David Dahan
David Dahan May 24, 2021 10:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NVO WILL BUY ORMP AT 30 $
Petri Kiljunen
Petri Kiljunen Feb 16, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
and Gals..! :D
Petri Kiljunen
Petri Kiljunen Feb 16, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
Ralf Adams
Ralf Adams Feb 16, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
Naim West
Naim West Feb 16, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Could be massive?? It will be now approved by FDA in US and soon EU all that remains is production cabability which was surprisingly not ready for such a demand (only US) so IMO this WILL exploded 10 fold what NN has expected., maybe more. Where do you find a obesity drug that helps? What obesity formulars has ever worked? This actually dos work.. Get ready!!!
christopher brown
christopher brown Aug 01, 2019 1:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very good long term investment
Jorgen Andersen
Jorgen Andersen Feb 06, 2019 4:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone got a view on how much the plans to reduce medical prices will affect the share price ?
Jens Kramer
Jens Kramer Feb 06, 2019 4:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My bet is that the stock price will have an increase in growth on the long term. Not sure about short term as they might need to spend to expand production, however, they might get subsidies for this.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email